Business
Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
CAMBRIDGE, Mass., June 24, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today unveiled additional data indicating that its lead development candidate, EB-003, acts as an agonist of the serotonin receptor 5-HT1B, in addition to its other previously disclosed receptor engagement activities. The 5-HT1B recep
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c6f384630924fed0db7d4a5f23a28eee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CzRvpvglBHdk1LhRgt4aRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c6f384630924fed0db7d4a5f23a28eee","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TY3VPdmTJ90rsuWDz_j7vA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/c6f384630924fed0db7d4a5f23a28eee","width":1024,"height":512}},"lazy":false},{"type":"text","content":"EB-003 revealed to also act as an agonist of the serotonin receptor 5-HT1B, a validated target of drugs approved to treat major depressive disorder and a variety of neurological conditions including Parkinson’s disease, migraines, and cluster headaches","length":252,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., June 24, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today unveiled additional data indicating that its lead development candidate, EB-003, acts as an agonist of the serotonin receptor 5-HT1B, in addition to its other previously disclosed receptor engagement activities. The 5-HT1B receptor is a recognized therapeutic target for treating several central nervous system ("CNS") conditions, including major depressive disorder, Parkinson’s disease, migraines, and cluster headaches.","length":741,"tagName":"p"},{"type":"text","content":"The study results demonstrated agonism of 5-HT1B by EB-003 (EC50 = 110 nM) and added to the existing receptor engagement data supporting that EB-003 acts as a partial agonist of the 5-HT2A receptor, which is key to the compound’s potential ability to elicit neuroplastogenic effects without inducing adverse hallucinogenic outcomes.","length":332,"tagName":"p"},{"type":"text","content":""The 5-HT1B receptor, found predominantly in the frontal cortex, basal ganglia and hippocampus, is a validated ther...